QGEN - キアゲン （Qiagen N.V.） キアゲンQGENのチャート
QGENの企業情報
| symbol | QGEN |
|---|---|
| 会社名 | Qiagen N.V. （キアゲン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 キアゲン（QIAGEN N.V.）はサンプルと分析技術を提供する持株会社。サンプルとアッセイキット及び自動化された計測システムなどの消耗品は顧客が生の生物学的サンプルを価値のある分子情報に変換することを可能にする。同社は分子診断研究所、法医学、獣医診断と食品安全などの分野における応用試験の顧客、医薬品の研究開発グループ、及び学術研究者の４つの顧客クラス向けにサービスを提供する。同社は100以上の国において製品を販売する。同社は試料調製とその後の分析に使用されるほぼすべての｢QIAGEN｣製品の加工を自動化する複数の機器ソリューション及び500種以上の主要消耗品を提供する。平成24年5月3日、同社はAmniSure International LLCを買収した。 キアゲンは、オランダの試薬・解析技術メ―カ―。カ―トリッジや自動化精製のフォ―マットなどの同社の技術は、生体サンプルからDNA、RNAなどの分析に使用される。また、ヒトおよび獣医学の分子診断のための診断キット、検査、分析を提供。製品は、学術研究市場、製薬会社およびバイオテクノロジ―企業のほか、分子診断研究所へ販売される。 QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide. |
| 本社所在地 | Hulsterweg 82 Venlo 5912 PL NLD |
| 代表者氏名 | Manfred E. Karobath Manfred E. Karobath |
| 代表者役職名 | Independent Chairman of the Supervisory Board |
| 電話番号 | +31 77-355-6600 |
| 設立年月日 | 35156 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 年 |
| 従業員数 | 4559人 |
| url | www.qiagen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/qgen |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 499.98300 |
| 終値（lastsale） | 35.66 |
| 時価総額（marketcap） | 8096103760 |
| 時価総額 | 時価総額（百万ドル） 8289.08 |
| 売上高 | 売上高（百万ドル） 1481.604 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 9151.382 |
| 当期純利益 | 当期純利益（百万ドル） 190.38000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Qiagen NV revenues increased 10% to $720.8M. Net income increased from $31.6M to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other income net increase from $7.4M (expense) to $25M (income) General and administrative integration decrease of 13% to $45.4M (expense). |
QGENのテクニカル分析
QGENのニュース
Angle PLC announces Study using Parsortix in head and neck cancer 2022/09/28 06:00:00 Accesswire
ANGLE plc STUDY USING PARSORTIX DEMONSTRATES IMPORTANCE OF BIOMARKER-INDEPENDENT CTC ISOLATION IN HEAD AND NECK CANCER EMT status of CTCs found to provide additional insight to tumour tissue biopsy Potential role of CTC EMT biomarkers as therapeutic targets GUILDFORD, UK / ACCESSWIRE / September 28, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma (HNSCC) which characterised the epithelial-mesenchymal transition (EMT) status of circulating tumour cells (CTCs). EMT is clinically significant due to its role in tumour progression and invasion, the development of metastasis, metabolic reprogramming, immune evasion, and resistance of cancer cells to therapy. The study used the Parsortix ® system to harvest CTCs from peripheral blood samples from 20 treatment-naïve HNSCC patients at baseline prior to surgery.
Molecular Diagnostics Market to Reach US$ 37.19 Bn by 2028, TMR Study 2022/09/26 12:33:00 Accesswire
WILMINGTON, DE / ACCESSWIRE / September 26, 2022 / Transparency Market Research Inc. - Rising use of automation in various healthcare and biotech research processes is creating attractive opportunities in the global molecular diagnostics market . This trend is further bolstered by the rising need for incorporating automation for facilitating various processes, including extraction of DNA, amplification, and analyzing and recording healthcare data. These automated systems offer various benefits, such as higher efficiency, precise output, and reduced time required for gaining results. Based on a recent research report, the global molecular diagnostics market is estimated to rise at a CAGR of 11.1% over the forecast period of 2021 to 2028. Get Exclusive PDF Sample Copy of Molecular Diagnostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783 Growing adoption of molecular diagnostic devices in various diagnostic laboratories, biotech and pharma companies, hospitals, and research and academic institutes is creating growth opportunities for players in the global molecular diagnostics market in developed economies.
Molecular Diagnostics Global Market Report 2022 2022/09/23 13:20:00 GlobeNewswire
The major players in the molecular diagnostics market are Becton, BioMérieux SA. , Danaher Corporation, Grifols, Hologic Inc. , Novartis AG, QIAGEN, Siemens Healthcare GmbH, Abbott, and Dickinson and Company. The major players in the molecular diagnostics market are Becton, BioMérieux SA. , Danaher Corporation, Grifols, Hologic Inc. , Novartis AG, QIAGEN, Siemens Healthcare GmbH, Abbott, and Dickinson and Company.
Microfluidics Global Market Report 2022 2022/09/22 17:17:00 GlobeNewswire
Major players in the microfluidics market are Illumina, Inc. , PerkinElmer, Inc. , Agilent Technologies, Inc. , Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Elveflow, Cellix Ltd. , Fluidigm Corporation, Fluigent SA, Zeon Corporation, Innovative Biochips, LLC, Dolomite Microfluidics, Idex Corporation, and UFluidix. Major players in the microfluidics market are Illumina, Inc. , PerkinElmer, Inc. , Agilent Technologies, Inc. , Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Elveflow, Cellix Ltd. , Fluidigm Corporation, Fluigent SA, Zeon Corporation, Innovative Biochips, LLC, Dolomite Microfluidics, Idex Corporation, and UFluidix.
With 12.1% CAGR, Biomarkers Market Size worth USD 97.51 Billion in 2026 2022/09/21 11:11:59 Benzinga
Pune, India, Sept. 21, 2022 (GLOBE NEWSWIRE) -- The global biomarkers market size was USD 39.10 billion in 2018 and is expected to reach USD 97.51 billion by 2026, exhibiting a CAGR of 12.1% over the forecast period. The rise can be attributed to an escalation in the diagnostic applications of biomarkers. This is further being supplemented by the growing prevalence of cancer and an increase in the number of research and development activities. Key Industry Development: May 2021 – QIAGEN N.V. rolled out its tissue companion diagnostic approved by the FDA. The solution was released for identifying the mutation of KRAS G12C in NSCLC tumors. The diagnostic would help in the expansion of precision medicine portfolio for lung cancer. Get a Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biomarkers-market-102173 Report Scope: Report Coverage Details Forecast Period 2019 to 2026 Forecast Period 2019 to 2026 CAGR 12.1% 2026 Value Projection USD 97.51 billion Base Year 2018 Market Size in 2018 USD 39.
Sharon Robins Joins Precipio''s Products Division as Senior Director of Laboratory & Hospital Sales 2022/08/24 15:00:00 Benzinga
NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO ) , welcomes Sharon Robins as the Company''s Senior Director of Laboratory & Hospital Sales for the Product''s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (annualized run rate), Ms. Robins will be tasked with managing that relationship and ensuring its success. Coming from Qiagen, a market leader in the diagnostic reagents field, Ms. Robins brings with her a strong background in multiple leadership positions in diagnostic product sales. During her tenure at Qiagen she was responsible for over $100M in annual revenues. Sharon has a strong background in diagnostics distribution, previously holding senior sales positions at Quest Diagnostics, ThermoFisher, and Life Technologies. In those roles she led teams and was responsible for triple-digit million-dollar revenues. "We are extremely fortunate to have attracted an executive of Sharon''s caliber to our company.
New Products Posted to GenomeWeb: Qiagen, Boston Heart Diagnostics, Bio-Techne, More 2022/08/19 17:05:08 GenomeWeb
New products posted to GenomeWeb for the week of Aug. 15, 2022.
QIAGEN N.V.: QIAGEN Issues 2021 Sustainability Report 2022/08/18 20:10:00 Finanz Nachrichten
Greenhouse gas emissions intensity lowered by 16% and plastic footprint down 9.6% vs. 2020 Commitment to ambitious climate goals: Net-zero by 2050, Scope 1 and 2 emissions down 42% by 2030 Widenin…
QIAGEN Issues 2021 Sustainability Report 2022/08/18 20:05:00 Business Wire
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2021 Sustainability Report, outlining significant achievements in the areas of Environment, Social and Governance (ESG) as part of its strategy to become a stronger and more sustainable leader in providing Sample to Insight solutions that unlock valuable molecular insights for customers in the Life Science and Molecular Diagnostics industries. “As the world faces key challenges, from i
Qiagen launches test to differentiate between monkeypox, other pathogens 2022/08/15 20:17:04 Seeking Alpha
Qiagen (QGEN) on Monday launched a syndromic test to differentiate between monkeypox and five other pathogens that produce similar symptoms.The Germany-based molecular testing…
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments 2021/07/07 20:05:00 Business Wire
GERMANTOWN, Md., & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #lifescience--QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
Aktie von Qiagen legt um 0,40 Prozent zu 2021/07/07 12:32:00 FinanzNachrichten
Die Qiagen-Aktie notiert am Mittwoch etwas fester. Das Papier kostete zuletzt 42,57 Euro. Ein Kursgewinn in Höhe von 17 Cent erfreut derzeit die Aktionäre von Qiagen. Zur Stunde wird die Aktie am A
White & Case Advises QIA on Participation in Age of Learnings US$300 Million Financing Round | White & Case LLP 2021/07/06 09:56:43 CompanyNewsHQ
Global law firm White & Case LLP has advised Qatar Investment Authority (QIA), the sovereign wealth fund of the State View post on CompanyNewsHQ : White & Case Advises QIA on Participation in Age of Learnings US$300 Million Financing Round | White & Case LLP